ASH 2023 | NHL: What’s hot at ASH 2023?
Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of key topics in non-Hodgkin lymphoma (NHL) from the 65th ASH Annual Meeting, with a particular focus on bispecific antibodies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: ADC Therapeutics, Bristol Myers Squibb/Celgene, Caribou Biosciences, AbbVie, DeNovo, Daiichi Sankyo, Genentech, Inc., Genmab, Gilead/Kite, Janssen, Merck, Novartis, Takeda, Regeneron, AstraZeneca, Gilead Sciences/Kite Pharma
Research Funding: Bristol Myers Squibb/Celgene, Caribou Biosciences, Daiichi Sankyo, Genentech, Inc., Genmab, Gilead/Kite, Janssen, Merck, Novartis, Takeda, Gilead Sciences/Kite Pharma
